Overview

Single-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence

Status:
RECRUITING
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
To assess 1-year recurrence-free survival (RFS) in patients with hepatocellular carcinoma (HCC) who are at high risk of Inguinal orchiectomy recurrence usingTACE combined with icaritin
Phase:
PHASE2
Details
Lead Sponsor:
Zhujiang Hospital